Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2018

27.02.2018 | Onkologie | editorial

Revival of anti-angiogenic therapies in cancer

News from an old therapeutic concept—part 2

verfasst von: MD PhD Andreas Pircher

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Referring to the last issue presenting state of the art reviews [ 1] on the use of anti-angiogenic drugs in colorectal [ 2], urological [ 3, 4] and breast cancer [ 5] as well as in angiosarcomas [ 6], the present issue extends the topic to additional angiogenesis-dependent malignancies. Hereby, ovarian cancer and non-small cell lung cancer (NSCLC) represent two highly vascularized tumor entities where anti-angiogenic therapies form a robust backbone for the treatment of advanced stage disease mostly in combination with chemotherapy or newer therapeutic therapies. …
Literatur
1.
Zurück zum Zitat Pircher A. Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept. Memo. 2017;10(4):185–6. CrossRef Pircher A. Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept. Memo. 2017;10(4):185–6. CrossRef
2.
Zurück zum Zitat Stragier E, Prenen H. Antiangiogenic therapies in colorectal cancer. Memo. 2017;10(4):213–7. CrossRef Stragier E, Prenen H. Antiangiogenic therapies in colorectal cancer. Memo. 2017;10(4):213–7. CrossRef
Metadaten
Titel
Revival of anti-angiogenic therapies in cancer
News from an old therapeutic concept—part 2
verfasst von
MD PhD Andreas Pircher
Publikationsdatum
27.02.2018
Verlag
Springer Vienna
Schlagwort
Onkologie
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0394-0